A national alliance of patient organizations with a shared goal of equitable and consistent access for all Canadians to safe and effective medicines that improve patient outcomes.

Read More

Issues

Pharmacare & Pharmaceutical Reform

We support reforms which will allow  all Canadians to access the medicines they need when needed, equitably and consistently, as outlined in our core positions and principles, and in formal submissions.
Pharmacare Advisory Council:
BMC’s Position Points on Key Recommendations

Statement Regarding National Pharmacare Interim Report Announcement

National Pharmacare Implementation: Patient Perspectives and Considerations

Positions and Considerations Regarding National Pharmacare Funding Options

BMC Survey:
Patient Perspectives on National Pharmacare: Current Challenges, Goals and Implementation Issues

BMC Positions:
Pharmacare Position Points: September 2019

Principles & Considerations Regarding Pharmacare

Submission: Standing Committee on Health

Joint Discussion Paper:
Better Pharmacare For Patients: Evaluating Policy Options (Français)

Pharmaceutical Pricing

We support a strong regulatory framework for pharmaceutical pricing which ensures value and an environment which delivers the best possible care for patients.
BMC Positions:
Submission Regarding PMPRB Revised Draft Guidelines (August 2020)

Letter to the Minister of Health (June 19, 2020) (français)

Submission to the House of Commons Standing Committee on Health (May 2020)

Draft Guidelines to Implement the Patented Medicines Regulations, as amended (February 2020)

Proposed Patented Medicines Regulations (February 2018)

PMPRB Modernization (October 2016)

Safety & Supply

We a support a national regulatory framework which protects Canadian patients, including addressing supply issues like drug shortages which put patients at risk.
BMC Positions:
Submission to the House of Commons Standing Committee on Health (May 2020)

Letter to the Prime Minister Regarding COVID-19 and Drug Shortages (March 2020)

Submission to the Food and Drug Administration Regarding Drug Importation (March 2020)

Submission to the House of Commons Standing Committee on Health (March 2012)